• Published 2015

Interim safety results from TRUST , a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer ( NSCLC )

@inproceedings{Ardizzoni2015InterimSR,
  title={Interim safety results from TRUST , a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer ( NSCLC )},
  author={Andrea Ardizzoni and Evangelia Razis and Mikhail Lichinitser and Yılmaz and Uğur and Grigorescu and Jos{\'e} Luis. and Jana Skři{\vc}kov{\'a} and Guadalupe Cervantes and Jennifer Moughan and Curran and Werner-Wasik and Komaki},
  year={2015}
}
Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) Ardizzoni, Andrea1 Razis, Evangelia2 Lichinitser, Mikhail3 Yilmaz, Ugur4 Grigorescu, Alexandru C.5 Morero, José Luis6 Skrickova, Jana7 Cervantes, Guadalupe8 Gottfried, Maya9 Van Meerbeeck, Jan10 1 University of Parma, Parma, Italy 2 Hygeia Hospital, Athens, Greece 3 NN Blochin Russian Oncology Research Center, Moscow, Russia 4 Dokuz Eylul University Medical… CONTINUE READING